Drug
Risvutatug rezetecan clinical trials
Also written HS-20093 and GSK5764227.
Keep track of what changes. Save the risvutatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2025 (7)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 2
Hansoh BioMedical R&D Company (13) · GlaxoSmithKline (5) · Zhejiang University (1) · Nader Sanai (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Shanghai Hansoh Biomedical Co., Ltd (1)
Often tested with
Tested in the same studies.
Remzistotug (1) · Dostarlimab (1) · Belrestotug (1) · Nelistotug (1) · Nimotuzumab (1) · Adebrelimab (1) · Ivonescimab (1) · Zeprumetostat (1)
Studies
Open first, then newest update. How each study uses risvutatug rezetecan is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingPhase 3GlaxoSmithKlineNCT07099898Written as Risvutatug rezetecan (Ris-Rez)
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)RecruitingPhase 1/2GlaxoSmithKlineNCT06885034Written as Risvutatug Rezetecan
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Written as Risvutatug rezetecan (Ris-Rez)
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingPhase 1/2GlaxoSmithKlineNCT07602855Written as Risvutatug rezetecan
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Written as HS-20093
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07621601Written as HS-20093 for Injection
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07464327Written as HS-20093
- HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07462923Written as HS-20093 for injection
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesRecruitingEarly Phase 1Nader SanaiNCT07268053Written as Risvutatug rezetecan
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as HS-20093 for Injection
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07186452Written as HS-20093
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07115446Written as HS-20093
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06769425Written as HS-10502 + HS-20093
- HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06112704Written as HS-20093
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT05830123Written as HS-20093
- ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06007729Written as HS-20093
- ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06001255Written as HS-20093
- A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT06526624Written as HS-20093
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051Written as GSK5764227
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedPhase 3Hansoh BioMedical R&D CompanyNCT06935409Written as HS-20093
See all 23 studies that test risvutatug rezetecan →
Given in every arm · 10 — risvutatug rezetecan is usual care beside what is tested
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625Written as HS-20093 for Injection
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT07824882Written as HS-20093 for Injection
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 2University Health Network, TorontoNCT07408063Written as GSK5764227
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)RecruitingPhase 1/2GlaxoSmithKlineNCT07602777Written as Ris-Rez
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingPhase 1GlaxoSmithKlineNCT07277270Written as GSK5764227
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Written as Ris-Rez
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06963502Written as HS-20093
- ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06825624Written as HS-20093
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576Written as HS-20093
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06332170Written as HS-20093
Codes
What other systems call risvutatug rezetecan · ClinicalTrials.gg INT015531
- UNII (FDA) 7T9A6CKG67RISVUTATUG REZETECANOne source FDA
- NCI Thesaurus C187121Risvutatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7T9A6CKG67 | RISVUTATUG REZETECAN | One source FDA |
| NCI Thesaurus | C187121 | Risvutatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.